WASHINGTON, Dec 2 (Reuters) - Nucryst Pharmaceuticals Corp., a wholly-owned subsidiary of Westaim Corp. (WED.TO: Quote, Profile, Research) , on Friday said that it is planning an initial public offering of 5.77 million common shares for between $12 and $14 per share.